“Patients with advanced NSCLC deserve access to these therapeutic advances. Our purpose is not just doing just research for the sake of research, but we also have to implement the research,” he said.
The SWOG S0819 trial was supported by the National Institutes of Health and Bristol-Myers Squibb. Dr. Herbst disclosed consulting with the company. He is also a member of the Oncology Report editorial board. Dr. Pirker disclosed receiving honoraria, speaker’s fees, and consulting with various companies, not including Bristol-Myers Squibb.